| Outcome | Patients (responders/all) | Response rate (%) | Range of response (%) |
| Primary end pointa | 1154/3184 | 36.2 | 17.5–48.6 |
| SRI-4 | 984/2503 | 39.3 | 32.3–48.4 |
| SRI-5 | 400/1424 | 28.1 | 20.4–39.3 |
| SRI-6 | 389/1424 | 27.3 | 18.9–37.4 |
| BICLA | 344/1088 | 31.6 | 25.7–36.1 |
| Patients reducing prednisone to ≤7.5 mg/day | 141/919 | 15.3 | 12–26.6 |
| Normalization of anti-dsDNA antibodies | 83/1055 | 7.9 | 5.7–11.9 |
| Normalization of C3 | 126/616 | 20.5 | 14–22.4 |
| Normalization of C4 | 59/347 | 17 | 7.7–21.9 |
| Outcome | Patients (responders/all) | Response rate (%) | Range of response (%) |
| Primary end pointa | 1154/3184 | 36.2 | 17.5–48.6 |
| SRI-4 | 984/2503 | 39.3 | 32.3–48.4 |
| SRI-5 | 400/1424 | 28.1 | 20.4–39.3 |
| SRI-6 | 389/1424 | 27.3 | 18.9–37.4 |
| BICLA | 344/1088 | 31.6 | 25.7–36.1 |
| Patients reducing prednisone to ≤7.5 mg/day | 141/919 | 15.3 | 12–26.6 |
| Normalization of anti-dsDNA antibodies | 83/1055 | 7.9 | 5.7–11.9 |
| Normalization of C3 | 126/616 | 20.5 | 14–22.4 |
| Normalization of C4 | 59/347 | 17 | 7.7–21.9 |
aAs defined by each study
SRI-4: SLE Responder Index 4 (reduction of ≥4 in SELENA-SLEDAI or SLEDAI-2K, no worsening in PGA, no new A or two new B scores in the British Isles Lupus Assessment Group, BILAG)
SRI-5: as above with ≥5 reduction in SELENA-SLEDAI or SLEDAI-2K
SRI-6: as above with ≥6 reduction in SELENA-SLEDAI or SLEDAI-2K
BICLA: (BILAG-based Combined Lupus Assessment) improvement from baseline in the BILAG-2004 score, no worsening in SLEDAI-2K and PGA, no unpermitted changes in concomitant medications.
| Outcome | Patients (responders/all) | Response rate (%) | Range of response (%) |
| Primary end pointa | 1154/3184 | 36.2 | 17.5–48.6 |
| SRI-4 | 984/2503 | 39.3 | 32.3–48.4 |
| SRI-5 | 400/1424 | 28.1 | 20.4–39.3 |
| SRI-6 | 389/1424 | 27.3 | 18.9–37.4 |
| BICLA | 344/1088 | 31.6 | 25.7–36.1 |
| Patients reducing prednisone to ≤7.5 mg/day | 141/919 | 15.3 | 12–26.6 |
| Normalization of anti-dsDNA antibodies | 83/1055 | 7.9 | 5.7–11.9 |
| Normalization of C3 | 126/616 | 20.5 | 14–22.4 |
| Normalization of C4 | 59/347 | 17 | 7.7–21.9 |
| Outcome | Patients (responders/all) | Response rate (%) | Range of response (%) |
| Primary end pointa | 1154/3184 | 36.2 | 17.5–48.6 |
| SRI-4 | 984/2503 | 39.3 | 32.3–48.4 |
| SRI-5 | 400/1424 | 28.1 | 20.4–39.3 |
| SRI-6 | 389/1424 | 27.3 | 18.9–37.4 |
| BICLA | 344/1088 | 31.6 | 25.7–36.1 |
| Patients reducing prednisone to ≤7.5 mg/day | 141/919 | 15.3 | 12–26.6 |
| Normalization of anti-dsDNA antibodies | 83/1055 | 7.9 | 5.7–11.9 |
| Normalization of C3 | 126/616 | 20.5 | 14–22.4 |
| Normalization of C4 | 59/347 | 17 | 7.7–21.9 |
aAs defined by each study
SRI-4: SLE Responder Index 4 (reduction of ≥4 in SELENA-SLEDAI or SLEDAI-2K, no worsening in PGA, no new A or two new B scores in the British Isles Lupus Assessment Group, BILAG)
SRI-5: as above with ≥5 reduction in SELENA-SLEDAI or SLEDAI-2K
SRI-6: as above with ≥6 reduction in SELENA-SLEDAI or SLEDAI-2K
BICLA: (BILAG-based Combined Lupus Assessment) improvement from baseline in the BILAG-2004 score, no worsening in SLEDAI-2K and PGA, no unpermitted changes in concomitant medications.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
